.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Baxter
Chubb
Boehringer Ingelheim
Cipla
McKesson
Queensland Health
Healthtrust
Merck

Generated: July 26, 2017

DrugPatentWatch Database Preview

Eisai Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?

EISAI INC has seventeen approved drugs.

There are thirty US patents protecting EISAI INC drugs and there have been two Paragraph IV challenges on EISAI INC drugs in the past three years.

There are four hundred and seventy-seven patent family members on EISAI INC drugs in forty-eight countries.

Summary for Applicant: Eisai Inc

Patents:30
Tradenames:13
Ingredients:11
NDAs:17
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-003Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
LUSEDRA
fospropofol disodium
SOLUTION;INTRAVENOUS022244-001Dec 12, 2008DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
ACIPHEX
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-002Aug 19, 1999► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-001Nov 25, 1996► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-002Nov 25, 1996► Subscribe► Subscribe
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-001Nov 25, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for EISAI INC drugs

Drugname Dosage Strength Tradename Submissiondate
lorcaserin hydrochloride
Extended-release Tablets20 mg
BELVIQ XR
12/13/2016
perampanel
Tablets2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg
FYCOMPA
10/24/2016
rufinamide
Oral Suspension40 mg/mL
BANZEL
6/16/2014
donepezil hydrochloride
Tablets23 mg
ARICEPT
7/9/2013
rufinamide
Tablets100 mg, 200 mg and 400 mg
BANZEL
11/14/2012
donepezil hydrochloride
Orally Disintegrating Tablets5 mg and 10 mg
ARICEPT ODT
6/30/2010

Premature patent expirations for EISAI INC

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Eisai Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,451,776 Water soluble prodrugs of hindered alcohols► Subscribe
7,973,160Nitrogen-containing aromatic derivatives► Subscribe
8,372,981Nitrogen-containing aromatic derivatives► Subscribe
8,304,548Method for producing 1, 2-dihydropyridine-2-one compound► Subscribe
8,846,9065HT.sub.2C receptor modulators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eisai Inc Drugs

Country Document Number Estimated Expiration
Russian Federation2265015► Subscribe
Poland347211► Subscribe
South Korea100870681► Subscribe
Japan4191741► Subscribe
World Intellectual Property Organization (WIPO)2014058441► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eisai Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013017Lithuania► SubscribePRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029
01/009Ireland► SubscribePRODUCT NAME: PANRETIN-ALITRETINOIN
90021-4Sweden► SubscribePRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT; REG. NO/DATE: EU/1/11/678/001-002 20110317
1300396/01Switzerland► SubscribePRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012
2011 00022Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Citi
Covington
Colorcon
Accenture
McKinsey
US Army
Merck
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot